- Home
- BQ vs SNGX Comparison
BQ vs SNGX Comparison
Compare BQ & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- SNGX
- Stock Information
- Founded
- BQ 2008
- SNGX 1987
- Country
- BQ China
- SNGX United States
- Employees
- BQ N/A
- SNGX N/A
- Industry
- BQ Other Specialty Stores
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- SNGX Health Care
- Exchange
- BQ Nasdaq
- SNGX Nasdaq
- Market Cap
- BQ 6.0M
- SNGX 6.5M
- IPO Year
- BQ 2020
- SNGX 1987
- Fundamental
- Price
- BQ $2.20
- SNGX $2.16
- Analyst Decision
- BQ
- SNGX
- Analyst Count
- BQ 0
- SNGX 0
- Target Price
- BQ N/A
- SNGX N/A
- AVG Volume (30 Days)
- BQ 11.4K
- SNGX 199.2K
- Earning Date
- BQ 04-29-2025
- SNGX 05-09-2025
- Dividend Yield
- BQ N/A
- SNGX N/A
- EPS Growth
- BQ N/A
- SNGX N/A
- EPS
- BQ N/A
- SNGX N/A
- Revenue
- BQ $81,208,354.00
- SNGX $119,371.00
- Revenue This Year
- BQ N/A
- SNGX N/A
- Revenue Next Year
- BQ N/A
- SNGX N/A
- P/E Ratio
- BQ N/A
- SNGX N/A
- Revenue Growth
- BQ N/A
- SNGX N/A
- 52 Week Low
- BQ $1.62
- SNGX $1.68
- 52 Week High
- BQ $7.40
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- BQ 53.53
- SNGX 51.88
- Support Level
- BQ $1.79
- SNGX $1.97
- Resistance Level
- BQ $2.23
- SNGX $2.23
- Average True Range (ATR)
- BQ 0.20
- SNGX 0.17
- MACD
- BQ 0.06
- SNGX 0.02
- Stochastic Oscillator
- BQ 68.95
- SNGX 86.36
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).